

NDA 20-560

August 12, 2002

**FOSAMAX™
(Alendronate Sodium Tablets)**

**Citizen Petition: Administrative Record Update:
Dockets No. 99P-2547/CP1 and /PDN1**

Merck Research Laboratories

02P-0363

CP1

Michele R. Flicker, MD, PhD, FACP

Merck & Co., Inc.
P.O. Box 2000
Rahway NJ 07065-0900
Tel 732 594 1502
Fax 732 594 1030
michele_flicker@merck.com

August 12, 2002

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane
Room 1061
Rockville, MD 20852



NDA 20-560: FOSAMAX™ (Alendronate Sodium Tablets)

Citizen Petition: Administrative Record Update: Dockets No. 99P-2547/CP1 and /PDN1

Reference is made to the above cited Citizen Petition, originally submitted on June 14, 2002 under 21 CFR 10.30. Additional reference is made to a June 20, 2002 telephone conversation between Mr. Lyle Jaffe of the Dockets Management Branch, and Dr. Michele Flicker of Merck Research Laboratories (MRL, a Division of Merck & Co., Inc) and to a June 21, 2002 letter from the Dockets Management Branch.

In the above communications, the Agency noted that elements of the June 14, 2002 petition appeared to contain non-public information (eg elements in compliance with 21 CFR 314.50 and the January 1999, *Guidance for Industry Providing Regulatory Submissions in Electronic Format-NDA's*, but which are not required for a Citizen Petition). Such elements rendered the June 14 petition inconsistent with 21 CFR 10.30 (b); the petition would thus require amendment to be acceptable for filing.

Merck now submits for filing an amended Citizen Petition consistent with 21 CFR 10.30 (b). Nothing in this filing is trade secret, privileged, or confidential which may not be viewed by the public. Specifically, the Agency's minutes from a June 14, 2000 meeting between the Division of Metabolic and Endocrine Drug Products and Merck were written to be a position statement appropriate for public use. Thus, these minutes are referenced as "non-confidential" in the text of the Citizen Petition.

Sincerely yours,

A handwritten signature in black ink that reads 'Michele R. Flicker'.

Michele R. Flicker, MD, PhD, FACP
Director, Regulatory Affairs

Federal Express #1

Desk copy/att :
Mr. Randy Hedin, HFD-510, Room 14B-04
Dr. Bruce Schneider, HFD-510, Room 14B-04
Mr. Lyle Jaffe, HFA-305, Room 1061

Federal Express #2

Q:king/fosamax/nda/citizenpetition additionalcoverletter

Michele R. Flicker, MD, PhD, FACP

Merck & Co., Inc.
P.O. Box 2000
Rahway NJ 07065-0900
Tel 732 594 1502
Fax 732 594 1030
michele_flicker@merck.com

August 12, 2002

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane
Room 1061
Rockville, MD 20852



NDA 20-560: FOSAMAX™ (Alendronate Sodium Tablets)

Citizen Petition: Administrative Record Update: Dockets No. 99P-2547/CP1 and /PDN1

The undersigned, on behalf of Merck & Co., Inc., submits this petition under section 505A (c) of the Federal Food, Drug, and Cosmetic Act (FFDCA) and 21 CFR 10.30 to request the Commissioner of Food and Drugs to update the administrative records for the citizen petition dated July 28, 1999 (Docket No. 99P-2547/CP1) (Attachment 1) and the response dated January 6, 2000 (Docket No. 99P-2547/PDN1) (Attachment 2) from the Food and Drug Administration ("the Agency") to reflect the Agency's current position regarding the safety of the study of alendronate sodium (FOSAMAX™) in the pediatric population.

A. Action Requested

The petitioner requests that the October 27, 2000 Written Request to Merck Research Laboratories (MRL, a division of Merck & Co., Inc.) for clinical studies of alendronate sodium in pediatric patients with osteogenesis imperfecta, as well as the position articulated in a June 14, 2000 meeting between the Division of Metabolic and Endocrine Drug Products and Merck, be referenced in the administrative records of Dockets No. 99P-2547/CP1 and /PDN1 to reflect the Agency's current position regarding the appropriateness and safety of the study of alendronate sodium in the pediatric population.

With this submission, the petitioner does not request any other action or decision other than that these references be added to the administrative records of Dockets No. 99P-2547/CP1 and /PDN1.

B. Statement of Grounds

The citizen petition dated July 28, 1999 (Docket No. 99P-2547/CP1) referenced above requested that alendronate sodium be added to the to the priority section of the "List of Approved Drugs for which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population" ("the List"; Docket No. 98N-0056). In its January 6, 2000 response (Docket No. 99P-2547/PDN1), the Agency denied the request to add alendronate sodium to the priority section of the List, citing theoretical long-term safety concerns with the use of anti-resorptive therapy in the pediatric population and recommending against the study of alendronate sodium in pediatric populations.

After review of additional data, the Agency articulated its current position regarding the safety of the study of alendronate sodium in the pediatric population in a June 14, 2000 meeting with Merck. The non-confidential minutes from this meeting state that:

"There is currently insufficient information to evaluate the safety of alendronate in children. For this reason safety would constitute one of the primary objectives of any future studies in children. At this time we are unaware of any preclinical or clinical data that indicate that alendronate is clearly unsafe to use in the pediatric population. Our safety concerns are largely theoretical and relate primarily to the long residence time of the compound in bone, with possible consequences for skeletal growth, remodeling, and fracture healing.

The position of the Division is that studies of alendronate in children (for glucocorticoid induced osteoporosis, osteogenesis imperfecta, or possibly for other indications) would be safe to initiate, provided that an acceptable bone safety monitoring protocol is submitted and approved."

On October 27, 2000, the Office of Drug Evaluation II issued a Written Request to MRL for the study of alendronate in children with osteogenesis imperfecta.

On these grounds, Merck requests that the administrative records of Dockets No. 99P-2547/CP1 and /PDN1 reference the June 14, 2000 minutes and the October 27, 2000 Written Request, so that the Dockets may accurately reflect the current Agency opinion about the appropriateness and safety of the study of alendronate in children.

C. Environmental Impact

MRL claims that the Agency action requested in this petition would be subject to a categorical exclusion and would not require a further environmental assessment (EA) or abbreviated environmental assessment (AEA) in accordance with 21 CFR § 25.24(c)(2).


D. Economic Impact

This information will be submitted only when requested by the Commissioner following review of the petition. See 21 CFR § 10.30(b).

E. Certification

The undersigned certifies that, to the best of his/her knowledge and belief, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner which are unfavorable to the petition.

Sincerely yours,



Michele R. Flicker, MD, PhD
Director, Regulatory Affairs

Federal Express #1

**Attachment 1
July 28, 1999
Citizen Petition**

July 28, 1999

Dockets Management Branch (HFA-305)
Food and Drug Administration
Department of Health and Human Services
Room 1-46 Park Building
12420 Parklawn Drive
Rockville, MD 20857



**NDA 20-560: FOSAMAX™ (Alendronate Sodium Tablets)
Citizen Petition: Pediatric Priority List**

The undersigned, on behalf of Merck & Co., Inc., submits this petition under section 505A (c) of the Federal Food, Drug, and Cosmetic Act (FFDCA) to request the Commissioner of Food and Drugs to add alendronate sodium (Merck Research Laboratories' Fosamax™) to the priority section (Pediatric Priority List of Drugs Regulated by the Center for Drug Evaluation and Research) of the "List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population" ("the List") (Docket 98N-0056, dated May 20, 1998).

A. Action Requested

This petition requests the Commissioner to add alendronate to the priority section of the "List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population".

B. Statement of Grounds

On June 16, 1999, the Food and Drug Administration approved Fosamax™ (alendronate sodium) for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. This approved indication for Fosamax™ (alendronate sodium) also occurs in the pediatric population.

Fosamax™ (alendronate sodium) is now considered to be on the "the List" because it is approved for an indication in adults that also occurs in the pediatric population (as defined under "CONTENT OF THE LIST" Docket No. 98N-0056).

Alendronate should now be added to the priority section of the List. In its June 1998 "Guidance for Industry: Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food Drug and Cosmetic Act" (pages 8 and 9), FDA identified the criteria for determining which drugs are to be included in the Priority Section of the List. A drug needs to meet just one of the criteria to be included in the Priority Section of the List. Alendronate's fulfillment of a prioritization criterion is discussed below.

• **Alendronate is an agent which is approved for the treatment of glucocorticoid-induced osteoporosis, an indication for which additional therapeutic options for the pediatric population are needed.**

No therapy is currently approved for the treatment of glucocorticoid-induced (or other forms) of osteoporosis in children. Glucocorticoid-induced osteoporosis and associated fractures are a complication of oral glucocorticoid use in children. In addition, since one action of glucocorticoids is to prevent the attainment of peak bone mass, the true burden of illness in many pediatric patients may not be fully manifest until later in life. Glucocorticoid-induced osteoporosis occurs as a result of decreased osteoblast-mediated bone formation and increased osteoclast-mediated bone resorption, resulting in a net excess of resorption over formation.

In addition, glucocorticoid-induced myopathy and muscle weakness may also contribute to bone loss by removing the normal forces on bone that are produced by muscle contraction and may further increase fracture risk by increasing the propensity to fall. Finally, the underlying inflammatory disease (e.g. rheumatoid arthritis), or concomitant drug therapy, may also contribute to osteoporosis in patients treated with glucocorticoids.

The adverse effects of glucocorticoids on bone turnover have been documented in a number of longitudinal studies using different biochemical markers, alone or in combination, in children receiving glucocorticoids for a variety of diseases, including inflammatory bowel disease, asthma, and acute lymphoblastic leukemia.

Osteoporosis and associated fractures are a common complication in children (and adolescents) receiving supraphysiologic doses of glucocorticoids, for several reasons. First, childhood and adolescence are a time of high bone turnover, and glucocorticoids, by decreasing osteoblastic bone formation and increasing osteoclastic bone resorption, can produce a marked imbalance between the two processes, resulting in a negative calcium balance. Second, the use of glucocorticoids during adolescence may also prevent the patient from reaching his/her peak bone mass by decreasing bone modeling (1), due to the potent inhibitory effect of glucocorticoids on bone formation and, possibly, their inhibitory effect on GH secretion (2). Finally, a number of pediatric disorders for which glucocorticoids are prescribed such as juvenile chronic arthritis (mostly rheumatoid) and inflammatory bowel disease are independently associated with osteoporosis.

Asthma, juvenile rheumatoid arthritis, and inflammatory bowel disease are the most common chronic diseases that often require long-term glucocorticoid therapy. The prevalence of asthma is approximately 75 cases per 1,000 American children 16 years or younger, resulting in a total number of approximately 5.3 million affected children (3). However, although a relatively large number of asthmatic children may require treatment with glucocorticoids, only a very small proportion (approximately 1%) receives chronic therapy with oral glucocorticoids (4). In most cases, inhaled glucocorticoids are used, at relatively small doses, which have not been unequivocally associated with significant bone loss or increased fracture risk (5).

Juvenile rheumatoid arthritis is much less frequent than asthma, with a prevalence of about 134 cases per 100,000 American children \leq 16 years, or approximately 90,000 children (6). Approximately 30-40% of these children will require treatment with glucocorticoids, which are usually the last therapeutic resort. The prevalence of inflammatory bowel disease is slightly lower than that of juvenile rheumatoid arthritis, or approximately 100 cases per 100,000 American children \leq 16 years, or approximately 70,000 cases (3). Glucocorticoids are likely to be used in a majority of these patients. Other chronic diseases that may require glucocorticoid therapy, such as thrombocytopenic purpura, glomerulonephritis, or pemphigus occur at a much lower frequency.

Bisphosphonates in the Treatment of Glucocorticoid-induced Osteoporosis in Children

Only a few, small, open, mostly short-term studies of pharmacologic approaches to increasing BMD in children have been published. In a study of the effect of pamidronate in the treatment of progressive spinal osteoporosis in 12 children (median duration of therapy 5.2 years), treatment was associated with: 1) a normal pattern of linear growth; 2) marked increases in calcium balance sustained after the first year of therapy; and 3) increases in BMD at both axial and appendicular skeletal sites with a tendency of values to reach normal ranges, especially if treatment was started before puberty. In this study, complete reversal of vertebral deformities was also observed in some prepubertal children, similar to previous reports of improvement of vertebral shape observed in Cushing's disease after successful treatment. It appears that vertebrae in children have the potential to restore their structure as soon as the adverse stimulus is removed or treated, which does not occur in the adult skeleton (8, 9).

To date, there is limited experience on the use of alendronate in children receiving pharmacologic doses of glucocorticoids. However, some preliminary data suggest that alendronate may be beneficial in the treatment of children affected with disorders characterized by increased bone resorption. In a small, non-controlled study, four girls aged 6-13 years, on chronic glucocorticoid therapy for a variety of rheumatic diseases, received two courses of intravenous alendronate at the dose of 3.25 mg/day for 3 consecutive weeks every 3 months. Back pain resolved in all the patients within one week of the first alendronate administration. Clinical improvement was associated with significant increases in lumbar spine BMD after 12 months (average increase of 11.4% from baseline). Growth velocity was not negatively affected during the follow-up period and the treatment was well tolerated by all patients (10).

More recently, the same group of investigators presented preliminary data from a multicenter, open study of oral alendronate in 46 children with rheumatologic diseases (31 females, 15 males), aged 5 to 18 years, receiving glucocorticoid treatment for at least 6 months and with low BMD (at least 2 SD below the normal mean for their age). Oral alendronate was administered at the dose of 5 or 10 mg/day, depending on body weight. After 6 months of treatment, a significant increase in lumbar spine BMD was seen in 20 of 23 (87%) patients. Alendronate was well tolerated (11).

These results, albeit obtained in open studies in a limited number of children, are consistent with the positive effects of alendronate observed in adults (7).

Bisphosphonates for Other Forms of Osteoporosis in Children

In addition to glucocorticoid-induced osteoporosis, bisphosphonates (mainly pamidronate) have been used in other pediatric conditions characterized by bone loss and increased bone fragility, such as osteogenesis imperfecta (9, 12, 13), idiopathic juvenile osteoporosis (9), and juvenile chronic arthritis (eg. rheumatoid) (14). These studies have shown a positive effect to decrease bone turnover and increase bone mass. For example, in an uncontrolled observational study of 30 children aged 3 to 16 who had severe osteogenesis imperfecta, intravenous pamidronate produced a dramatic annualized increase of 42% in lumbar spine BMD, associated with a significant reduction in the incidence of vertebral fractures. The increase in spine BMD was also associated with a 27% increase per year in metacarpal cortical width (12).

The experience obtained with alendronate is more limited. However, preliminary data obtained in an uncontrolled, observational study appear to be quite positive. This study, reported at the recent First International Conference on Children's Bone Health, Maastricht, May 1999, examined the effects of alendronate in 18 children (12 boys and 6 girls), aged 9 to 17, affected with osteoporosis due to a variety of causes (glucocorticoid therapy = 8; juvenile idiopathic osteoporosis = 4; juvenile rheumatoid arthritis = 2; idiopathic hypercalciuria = 2; osteogenesis imperfecta = 2). Children received oral alendronate at doses ranging between 10 mg three times a week and 10 mg daily for up to 18 months. At the end of the observation period, lumbar spine BMD increased significantly, and radial BMD trended in a positive direction. Importantly, the fracture rate decreased from 2.9 to 0.2 fractures/patient/year ($p < 0.05$). Alendronate therapy was also well tolerated (Craig Langman, personal communication).

Safety Issues Specific to the Study Population

Bisphosphonates have been used in small groups of children with metabolic bone diseases including osteogenesis imperfecta, idiopathic juvenile osteoporosis and glucocorticoid-induced osteoporosis (9, 12-14). They have generally been well tolerated with minimal side effects. Specifically, deleterious effects on the growing skeleton have not been observed. Fracture healing has also not been adversely affected.

Bisphosphonates given as intravenous boluses to children prior to closure of the growth plates show characteristic bands of higher bone density at the metaphyses, especially in bones undergoing rapid growth (9). This effect has been described as "undertubulation", and consists of reduced remodeling of the shape of the long bones just below the metaphysis. When treatment is discontinued, remodeling does then occur leaving a normally shaped bone with a dense line of mineralization at the point where the growth plate was being formed during the time of treatment. This radiologic finding is not associated with any known clinical consequences. Skeletal maturation and linear growth proceed normally during treatment. In addition, bone biopsies obtained in children taking bisphosphonates show normal mineralization and lamellar structure (15).

No significant effects on the development of the teeth or dental arch in children have been reported in children treated with bisphosphonates. Delayed dental eruption has been described in newborn rats given subcutaneous pamidronate (at the dose of 1.25 µg/g/day) for 10-15 days; the architecture of these delayed teeth appeared to be normal (16). In contrast, slight disruptions in the formation of enamel and dentin have also been reported with etidronate, consistent with the drug's known effect to impair bone mineralization (17). Delayed eruption of the lower incisors, abnormality in the direction of eruption, and deformation of incisors, have also been reported in the offspring of rats treated with intravenous alendronate at a dose of 1 mg/kg (equivalent to an oral dose of approximately 140 mg/kg), but not at a lower dose of 0.1 mg/kg (18). These findings are unlikely to be relevant in children with the doses proposed for study.

C. Environmental Impact

MRL claims that the Agency action requested in this petition would be subject to a categorical exclusion and would not require a further environmental assessment (EA) or abbreviated environmental assessment (AEA) in accordance with 21 CFR § 25.24(c)(2).


D. Economic Impact

This information will be submitted only when requested by the Commissioner following review of the petition. See 21 CFR § 10.30(b).

E. Certification

The undersigned certifies that, to the best of his/her knowledge and belief, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner which are unfavorable to the petition.

Sincerely yours,



Michele R. Flicker, MD, PhD
Director, Regulatory Affairs

Q:flicker/citizen's petition/citpetfnl

Federal Express #1

Desk copy: Dr. Solomon Sobel, HFD-510, Room 14B-04 - Federal Express #2
Mr. Randy Hedin, HFD-510, Room 14B-04 - Federal Express #2

LIST OF REFERENCES*

1. Eastell R, Reid DM, Compston J, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. *J Int Med* 1998;244:271-92.
2. Bianchi ML, Bardare M, Galbiati E, Corona F, Cimaz R, Ortolani S. Bone development in juvenile rheumatoid arthritis. In: Schönau E, Matkovic V, eds. *Paediatric osteology. Prevention of osteoporosis - a paediatric task?* Singapore: Elsevier Science, 1998:173-81.
3. Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. *Vital Health Stat* 1998;10(199):77,78,123.
4. Walsh LJ, Wong CA, Cooper S, et al. Morbidity from asthma in relation to regular treatment: a community base study. *Thorax* 1999; 54:296-300.
5. Barnes PJ. Inhaled glucocorticoids for asthma. *New Engl J Med* 1995; 332:868-75.
6. American Juvenile Arthritis Organization: Tell me more about juvenile arthritis: the impact of juvenile arthritis [monograph online] 1997 [cited 1998 Apr 3]: [2 screens]. Available from URL: <http://www.arthritis.org/ajao/tellmemore/impact.asp>.
7. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. *N Engl J Med* 1998;339(5):292-9.
8. Papapoulos SE. Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. *Osteoporosis*. San Diego: Academic Press, 1996:1209-34.
9. Brumsen C, Hamdy NAT, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. *Med* 1997;76(4):266-83.
10. Falcini F, Trapani S, Ermini M, Brandt ML. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. *Calcif Tissue Int* 1996;58:166-9.
11. Cimaz R, Falcini F, Bardare M, et al. Alendronate improves bone mass in children with connective tissue diseases: preliminary results of a multicenter study [Abstract]. *Arthritis Rheum* 1997;40(Suppl 9):S240.
12. Glorieux FH, Bishop NJ, Plotkin H. et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. *N Engl J Med* 1998; 339:947-52.

13. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. *Acta Paediatr* 1998; 87:64-8.
14. Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. *Clin Exp Rheumatol* 1991;9:33-5.
15. van Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. *Radiology* 1992;184:249-54.
16. Grier RLIV, Wise GE. Inhibition of tooth eruption in the rat by a bisphosphonate. *J Dent Res* 1998;77(1):8-15.
17. Fouda N, Caracatsanis M, Alatli KI, Hammarstrom L. Mineralization disturbances of the developing rat molar induced by mono- and bisphosphonates. *J Biol Buccale* 1991; 19:106-15.
18. MRL Nonclinical Pharmacology and Toxicology Documentation, C. Reproductive Toxicity, I. Summary, January, 1994, Reference C-27: Intravenous peri- and postnatal study in rats.

* - All references are available upon request.

Attachment 2
January 6, 2000
FDA Letter



JAN 6 2000

Dr. Michele R. Flicker
Director, Regulatory Affairs
Merck & Co., Inc.
West Point, Pa. 19486

Re: Docket Nos. 99P-2547/CP1 and 98N-0056

Dear Dr. Flicker:

This letter responds to your citizen petition dated July 28, 1999, requesting that the Food and Drug Administration (FDA) add alendronate sodium to the priority section of the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population (Docket No. 98N-0056). The Agency has evaluated your petition and determined that it will not add alendronate sodium to the priority section of the list.

Although alendronate sodium is approved for glucocorticoid osteoporosis, an indication for which additional therapeutic options for the pediatric population are needed, we do not believe it is appropriate to study alendronate sodium in pediatric populations. Alendronate therapy in the pediatric population poses substantial long-term safety concerns regarding bone growth, fracture healing, structural integrity, and osteoblast recovery following steroid withdrawal. In general, given the safety concerns associated with many resorptive agents, including alendronate sodium, it may be wisest to treat children supportively, in anticipation of bone recovery following steroid withdrawal.

Accordingly, your petition is denied.

Sincerely yours,

Janet Woodcock, M.D.
Director
Center for Drug Evaluation and Research